This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Biontech US Inc., Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Stichting Het Nederlands Kanker Instituut—antoni Van Leeuwenhoek Ziekenhis. Active years: 2021-2025.
Company Filing History:
2 out of 9 
1 out of 16 
1 out of 1 Years Active: 2021-2025
Title: Ed Fritsch: Innovator in T Cell Manufacturing
Introduction
Ed Fritsch is a notable inventor based in Concord, MA (US), recognized for his contributions to the field of immunotherapy. He holds 2 patents that focus on T cell manufacturing compositions and methods. His work aims to enhance the generation of antigen-specific T cells, which can be pivotal in treating various conditions, including cancer.
Latest Patents
Fritsch's latest patents revolve around T cell manufacturing compositions and methods. These patents detail the generation of antigen-specific T cells through controlled ex vivo induction or expansion. This innovative approach can lead to highly specific and beneficial T cell therapies. The disclosed methods and therapeutic compositions are designed for treating subjects with cancer and other diseases, emphasizing the potential of personalized antigen-specific T cell therapy.
Career Highlights
Throughout his career, Ed Fritsch has worked with prominent organizations, including BioNTech US Inc. and the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. His experience in these institutions has significantly contributed to his expertise in T cell therapies and immunotherapy advancements.
Collaborations
Fritsch has collaborated with notable colleagues, including Marit M Van Buuren and Divya Reddy Lenkala. These partnerships have likely enriched his research and development efforts in the field of T cell manufacturing.
Conclusion
Ed Fritsch's innovative work in T cell manufacturing positions him as a key figure in the advancement of immunotherapy. His patents and collaborations reflect a commitment to improving therapeutic options for patients with cancer and other conditions.